ASCO Gastrointestinal Cancer Symposium

Treatment-emergent adverse effects following therapy with fostrox plus lenvatinib among those with hepatocellular carcinoma appear to be manageable in a phase 1a/2a study.

Investigators observe a benefit with durvalumab plus neoadjuvant chemotherapy among subgroups of patients regardless of microsatellite instability status in the phase 3 MATTERHORN trial.

Findings from the phase 3 FRESCO-2 trial support fruquintinib’s potential to provide an improved survival benefit and quality of life for those with previously treated metastatic colorectal cancer.

The DeFianCe trial is using DKN-01 plus bevacizumab and chemotherapy to determine if a clinical benefit would occur in patients with microsatellite stable colorectal adenocarcinoma.

Data from the phase 3 SKYSCRAPER-08 trial may support tiragolumab plus atezolizumab and chemotherapy as an alternative frontline treatment option for those with locally advanced or metastatic esophageal squamous cell carcinoma.

Combining ASKB589 with capecitabine, capecitabine, and sintilimab leads to no treatment discontinuation due to adverse effects among patients with gastric or gastroesophageal junction cancer in a phase 1/2 trial.

In the overall population and in patients with a PD-L1 CPS of 5 or greater who received nivolumab plus chemotherapy, overall survival and progression-free survival improved when compared with chemotherapy alone.

Results from an observational study found nivolumab plus chemotherapy helped enhance overall survival and progression-free survival for patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal adenocarcinoma.

An expert from the University of California, Los Angeles suggests that the NALIRIFOX may be a beneficial treatment for patients with pancreatic ductal adenocarcinoma.

Patients with metastatic pancreatic ductal adenocarcinoma who receive NALIRIFOX tend to have more gastrointestinal toxicity while nab-paclitaxel/gemcitabine results in more cytopenias, according to an expert from University of California, Los Angeles.

An expert from the University of California, Los Angeles described the purpose and design of the phase 3 NAPOLI-3 study, assessing NALIRIFOX in metastatic pancreatic ductal adenocarcinoma.

Findings from a phase 2 trial indicate that CTX-009 plus paclitaxel may produce an encouraging responses in patients with advanced biliary tract cancer, according to investigators.

Findings from the phase 3 BREAKWATER study indicate that encorafenib plus cetuximab and chemotherapy produces activity and is well-tolerated in metastatic colorectal cancer harboring BRAF V600E mutations.

Findings from the phase 2 MOUNTAINEER trial indicate that HER2 scoring algorithms may help in identifying which patients are suitable to receive tucatinib plus trastuzumab for metastatic colorectal cancer.

Findings from the phase 3 SUNLIGHT study highlight favorable overall survival and disease control rates with the use of bevacizumab plus trifluridine and tipiracil in metastatic colorectal cancer.

Novel, personalized, tumor-informed brPROPHET technology can assess molecular residual disease with greater sensitivity than other assays, according to initial data.

Patients with hepatocellular carcinoma treated from 2018 to 2021 experienced better outcomes than patients treated in the preceding decade, according to a recent study.

Molecular responders by G360 response algorithm with advanced colorectal cancer appear to have significantly lengthened time on treatment and overall survival with all regimens vs patients who did not respond.

An expert from the Mayo Clinic discusses how findings from the ongoing phase 3 MOUNTAINEER trial may enable access to tucatinib, trastuzumab, and chemotherapy in earlier lines of treatment for patients with HER2-positive metastatic colorectal cancer.

Investigators report evidence of early efficacy with SEA-CD40, chemotherapy, and pembrolizumab in patients with metastatic pancreatic ductal adenocarcinoma.

Patients with advanced biliary tract cancer experience modest clinical benefit following treatment with atezolizumab and cisplatin/gemcitabine with or without bevacizumab.

Patients diagnosed with locally advanced, hepatocellular carcinoma experience benefit in overall survival, progression-free survival, and time to disease progression following treatment with sorafenib and stereotactic body radiation therapy.

Patients with newly diagnosed, advanced biliary tract cancers do not have a statistically significant survival benefit following treatment with nab-paclitaxel plus gemcitabine and cisplatin.

A combination of liposomal irinotecan plus 5-fluorouracil, leucovorin, and oxaliplatin in the frontline yields a statistically significant survival benefit compared with nab-paclitaxel and gemcitabine in a population diagnosed with metastatic pancreatic ductal adenocarcinoma.

Patients with unresectable hepatocellular carcinoma experienced an improvement in several health-related quality of life measures following treatment with first-line tislelizumab compared with sorafenib.

Lenvatinib in combination with blank-microsphere transarterial chemembolization and sequential microwave ablation demonstrates encouraging preliminary activity in patients with hepatocellular carcinoma.

Envafolimab in combination with lenvatinib and transarterial chemoembolization demonstrated efficacy and safety among patients with unresectable hepatocellular carcinoma.

Findings from the phase 3 HIMALAYA trial indicate that durvalumab with or without tremelimumab remained efficacious regardless of the presence of anti-drug antibodies in unresectable hepatocellular carcinoma.

Findings from the phase 3 LEAP-002 study indicate that the addition of pembrolizumab to lenvatinib did not impact quality-of-life scores among patients with hepatocellular carcinoma.

Lenvatinib yields survival benefit in hepatocellular carcinoma following progression on immunotherapy.